Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem

This article was originally published in The Tan Sheet

Executive Summary

Net sales declined 4.6% to $79.6 mil. for the second quarter ended May 31, while earnings rose 6% to $6.1 mil. For the six months, sales slid 2.8% to $142 mil. as earnings rose 2.9% to $9.2 mil. Continuing poor sales of Sunsource supplements affected results, the firm says, along with low Ban antiperspirant sales due to a lack of advertising support until the second-half launch of Ban Naturals. The Chattanooga, Tenn.-based firm describes the launch of Dexatrim Natural as an early success and plans promotional support for the pHisoderm Blemish Patch (1"The Tan Sheet" April 17, p. 12). Chattem will introduce Gold Bond Fragrance Free Lotion in the third quarter, with marketing support in the fourth. The firm recently divested its Norwich aspirin brand to Jacksonville, Fla.-based Monticello Companies

You may also be interested in...



Dexatrim Natural Introduction Backed With $15 Mil. TV/Radio Campaign

TV and radio advertising for Dexatrim Natural Dietary Supplement highlights the product's "dual action" of curbing appetite and helping burn fat by speeding the body's metabolism, Chattem claims.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel